Search Within

Wungki Park

Formats
  1. Meeting Abstract (54)
  2. Journal Article (38)
  3. Review (5)
  4. Correspondence (3)
  5. Editorial (3)
Groups
  1. CTCR Scholars (103)
  2. Center for Pancreatic Cancer Research (103)
  3. Department of Medicine (103)
  4. Gastrointestinal Oncology Service (103)
  5. MSK Grad Students (103)
  6. Master of Science in Clinical and Translational Cancer Research (103)

More Groups

People
  1. Eileen O'Reilly (76)
  2. Anna Varghese (39)
  3. Kenneth Yu (35)
  4. Joanne Chou (27)
  5. William Jarnagin (27)
  6. Alice Wei (26)

More People

Years
  1. 2025 (12)
  2. 2024 (27)
  3. 2023 (18)
  4. 2022 (12)
  5. 2021 (11)
  6. 2020 (15)

More Years

Publications
  1. Journal of Clinical Oncology (35)
  2. Journal for ImmunoTherapy of Cancer (9)
  3. Annals of Oncology (5)
  4. Annals of Surgical Oncology (5)
  5. JCO Precision Oncology (5)
  6. Cancer (4)

More Publications

Publishers
  1. American Society of Clinical Oncology (40)
  2. Biomed Central Ltd (9)
  3. Oxford University Press (9)
  4. Springer (7)
  5. American Medical Association (5)
  6. Elsevier Inc. (5)

More Publishers

Results (103)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Dramatic, durable response to therapy in gBRCA2-mutated pancreas neuroendocrine carcinoma: Opportunity and challenge
    Journal Article

    Keane, F.; Bajwa, R.; Selenica, P.; Park, W.; Roehrl, M. H.; Reis-Filho, J. S.; Mandelker, D.; O’Reilly, E. M.
    npj Precision Oncology (2023)

    Fulltext@MSK | Save
  • Trial in progress: A phase 1, first-in-human, open-label, multicenter, dose-escalation and dose-expansion study of ASP3082 in patients with previously treated advanced solid tumors and KRAS G12D mutations
    Meeting Abstract

    Tolcher, A. W.; Park, W.; Wang, J. S.; Spira, A. I.; Janne, P. A.; Lee, H. J.; Gill, S.; LoRusso, P.; Herzberg, B.; Goldman, J. W.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Zolbetuximab plus gemcitabine and nab-paclitaxel (GN) in first-line treatment of claudin 18.2–positive metastatic pancreatic cancer (mPC): Phase 2, open-label, randomized study
    Meeting Abstract

    Park, W.; O'Reilly, E. M.; Furuse, J.; Li, C. P.; Oh, D. Y.; Garcia-Carbonero, R.; Roth, G.; Lee, H. J.; Bhattacharya, P. P.; Moran, D. M.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase II study of durvalumab and stereotactic ablative body radiotherapy (SABR) in locally advanced pancreatic adenocarcinoma (LA PDAC)
    Meeting Abstract

    Keane, F.; Schoenfeld, J. D.; Crowley, F.; O'Connor, C. A.; White, C.; Schwartz, C.; Brenner, R.; Larsen, M.; Park, W.; Varghese, A. M.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Adjuvant modified FOLFIRINOX (mFFX) for resected pancreatic cancer (PDAC): Real world outcomes (RWO)
    Meeting Abstract

    Keane, F.; Balogun, F.; O'Connor, C.; Crowley, F.; Chan, A.; Cowzer, D.; Chou, J. F.; Park, W.; Varghese, A. M.; Yu, K. H.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Phase II trial of maximal ablative irradiation because of encasement (MAIBE) for patients with potentially resectable locally advanced pancreatic cancer
    Meeting Abstract

    Reyngold, M.; Wei, A.; O'Reilly, E. M.; D'Angelica, M. I.; Drebin, J. A.; Soares, K.; Kingham, T. P.; Balachandran, V. P.; Varghese, A. M.; Park, W.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Clinical outcomes for IDH1 mutant biliary tract cancer (BTC) treated with contemporary systemic therapy
    Meeting Abstract

    Cowzer, D.; Huq, R.; Perry, M.; Keane, F.; Park, W.; El Dika, I. H.; Khalil, D.; Shia, J.; Sigel, C. S.; Bandlamudi, C.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Homologous recombination deficiency in pancreatic cancer: Poly (ADP-ribose) polymerase inhibition, checkpoint inhibition, or a combination of both?
    Correspondence

    Keane, F.; Park, W.; O'Reilly, E. M.
    JCO Precision Oncology (2022)

    Fulltext@MSK | Save
  • Generalizability of predictive versus prognostic indicators from published transcriptomic associations with tumor response to immune checkpoint inhibition
    Meeting Abstract

    Bortone, D.; Monette, A.; Tschernia, N.; Cogdill, A.; Najjar, Y.; Sweis, R. F.; Valpione, S.; Wennerberg, E.; Bommareddy, P.; Haymaker, C.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Optimal tumor metastatic gene programs in pancreatic cancer
    Meeting Abstract

    Jiménez-Sánchez, A.; Xie, Y.; Sharma, R.; Chu, T. Y.; Liu, V.; Park, W.; Hayashi, A.; Umeda, S.; Mazutis, L.; Nawy, T.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save